Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(20):1744-1750; doi:10.1093/jnci/91.20.1744
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Gnant, M. F. X.
Right arrow Articles by Bartlett, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gnant, M. F. X.
Right arrow Articles by Bartlett, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 20, 1744-1750, October 20, 1999
© 1999 Oxford University Press

REPORTS

Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases

Michael F. X. Gnant, Linda A. Noll, Kari R. Irvine, Markus Puhlmann, Richard E. Terrill, H. Richard Alexander, Jr., David L. Bartlett

Affiliations of authors: M. F. X. Gnant, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, and Department of Surgery, University of Vienna, Austria; L. A. Noll, R. E. Terrill, Laboratory Animal Medicine Section, Animal Sciences Branch, Division of Basic Sciences, National Cancer Institute; K. R. Irvine, M. Puhlmann, H. R. Alexander, Jr., D. L. Bartlett, Surgery Branch, Division of Clinical Sciences, National Cancer Institute.

Correspondence to: David L. Bartlett, M.D., National Institutes of Health, Bldg. 10, Rm. 2B07, Bethesda, MD 20892 (e-mail: dbart{at}nih.gov).

BACKGROUND: Several approaches to gene therapy for cancer have yielded promising results in rodent models. The translation of these results to the clinical realm has been delayed by the lack of tumor models in large animals. We investigated the pattern of transgene (i.e., foreign or introduced gene) expression and virus vector elimination after systemic gene delivery using a thymidine kinase-negative vaccinia virus in a rabbit model of disseminated liver metastases. METHODS: VX-2 rabbit carcinoma cells were maintained by serial transplantation in the thigh muscles of New Zealand White rabbits, and disseminated liver metastases were established by direct injection of tumor cells into the portal vein of the animals. Different doses of a recombinant thymidine kinase-negative vaccinia virus vector encoding the firefly luciferase reporter gene (i.e., transgene) were injected into tumor-bearing rabbits. Transgene activity in tumors and other organs was measured at multiple time points thereafter. The pattern of development of antibodies against the vaccinia virus vector was also examined. Two-tailed Student's paired t test was used for comparisons of transgene activity. RESULTS: Transgene expression was increased in tumors by at least 16-fold in comparison with expression in other tissues by day 4 after vector injection (all P<.001) and was maintained for approximately 1 week, providing evidence of tumor-specific gene delivery in this model. Rapid elimination of the circulating vector by the host immune system was observed. Anti-vector antibodies were detectable in serum as early as day 6 and were maintained for more than 3 months. CONCLUSIONS: Tumor-specific gene delivery is possible after systemic injection of a thymidine kinase-negative vaccinia virus vector in a model of rabbit liver metastases. Although the period of transgene expression appears limited because of a rapid immune response, the therapeutic window might be sufficient for an enzyme/prodrug gene therapy approach in clinical application.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
J. T. Mullen and K. K. Tanabe
Viral Oncolysis for Malignant Liver Tumors
Ann. Surg. Oncol., July 1, 2003; 10(6): 596 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Hel, W.-P. Tsai, A. Thornton, J. Nacsa, L. Giuliani, E. Tryniszewska, M. Poudyal, D. Venzon, X. Wang, J. Altman, et al.
Potentiation of Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cell Responses by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen
J. Immunol., December 15, 2001; 167(12): 7180 - 7191.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Hu, J. Lee, J. A. McCart, H. Xu, B. Moss, H. R. Alexander, and D. L. Bartlett
Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy
J. Virol., November 1, 2001; 75(21): 10300 - 10308.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Pierrefite-Carle, A. Gavelli, N. Brossette, P. Baque, D. Benchimol, A. Bourgeon, P. Staccini, and B. Rossi
Re: Cytosine Deaminase/5-Fluorocytosine-Based Vaccination Against Liver Tumors: Evidence of Distant Bystander Effect
J Natl Cancer Inst, March 15, 2000; 92(6): 494 - 495.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.